MetLife Investment Management’s Travere Therapeutics TVTX Stock Holding History

MetLife Investment Management’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.37M	Buy	45,979 +492	+1%	+$14.7K	0.01%	1257
2025 Q4	$1.74M	Sell	45,487 -7,091	-13%	-$231K	0.01%	1154
2025 Q3	$1.26M	Hold	52,578	–	–	0.01%	1325
2025 Q2	$778K	Buy	52,578 +3,290	+7%	+$54.5K	﹤0.01%	1449
2025 Q1	$883K	Buy	49,288 +4,577	+10%	+$92.9K	﹤0.01%	1427
2024 Q4	$779K	Buy	44,711 +3,568	+9%	+$63.1K	﹤0.01%	1549
2024 Q3	$576K	Buy	41,143 +311	+0.8%	+$3.24K	﹤0.01%	1709
2024 Q2	$336K	Buy	40,832 +7,843	+24%	+$52.8K	﹤0.01%	1941
2024 Q1	$254K	Sell	32,989 -5,449	-14%	-$46K	﹤0.01%	2063
2023 Q4	$346K	Hold	38,438	–	–	﹤0.01%	1909
2023 Q3	$344K	Hold	38,438	–	–	﹤0.01%	1856
2023 Q2	$590K	Buy	38,438 +5,931	+18%	+$108K	﹤0.01%	1586
2023 Q1	$731K	Hold	32,507	–	–	0.01%	1409
2022 Q4	$684K	Hold	32,507	–	–	0.01%	1437
2022 Q3	$801K	Hold	32,507	–	–	0.01%	1308
2022 Q2	$788K	Sell	32,507 -1,292	-4%	-$32.5K	0.01%	1344
2022 Q1	$871K	Buy	33,799 +12,475	+59%	+$331K	0.01%	1420
2021 Q4	$662K	Hold	21,324	–	–	0.01%	1343
2021 Q3	$517K	Hold	21,324	–	–	﹤0.01%	1501
2021 Q2	$311K	Hold	21,324	–	–	﹤0.01%	1865
2021 Q1	$532K	Buy	+21,324	New	+$589K	﹤0.01%	1490
2020 Q4	–	Sell	-21,324	Closed	-$394K	–	2310
2020 Q3	$394K	Buy	21,324 +2,482	+13%	+$48.2K	﹤0.01%	1496
2020 Q2	$385K	Hold	18,842	–	–	﹤0.01%	1523
2020 Q1	$275K	Hold	18,842	–	–	﹤0.01%	1518
2019 Q4	$268K	Hold	18,842	–	–	﹤0.01%	1817
2019 Q3	$218K	Hold	18,842	–	–	﹤0.01%	1897
2019 Q2	$379K	Hold	18,842	–	–	﹤0.01%	1648
2019 Q1	$426K	Hold	18,842	–	–	﹤0.01%	1555
2018 Q4	$426K	Hold	18,842	–	–	0.01%	1464
2018 Q3	$541K	Hold	18,842	–	–	0.01%	1485
2018 Q2	$514K	Buy	18,842 +2,439	+15%	+$65K	0.01%	1395
2018 Q1	$367K	Hold	16,403	–	–	﹤0.01%	1564
2017 Q4	$346K	Buy	+16,403	New	+$375K	﹤0.01%	1626

Other funds holding TVTX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

MetLife Investment Management's TVTX Position: Q1 2026 in Review

MetLife Investment Management increased its Travere Therapeutics (TVTX) stake by 1.1% in Q1 2026, buying an estimated $14.7K and bringing the position to 45,979 shares worth $1.37M. The position accounts for 0.01% of the portfolio, ranked #1257.

MetLife Investment Management first reported a position in TVTX in Q4 2017 and has held it in 33 quarters since. The position peaked at $1.74M in Q4 2025. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

MetLife Investment Management held 45,979 shares of Travere Therapeutics worth $1.37M as of Q1 2026.
MetLife Investment Management bought 492 Travere Therapeutics shares in Q1 2026, an estimated $14.7K.
Travere Therapeutics made up 0.01% of MetLife Investment Management's portfolio in Q1 2026, its #1257 holding.
MetLife Investment Management first reported a position in Travere Therapeutics in Q4 2017 and has held it in 33 quarters since.
MetLife Investment Management's Travere Therapeutics position peaked at $1.74M in Q4 2025.
260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.